---

---

---

---

Syros Pharmaceuticals, Inc. (the "Issuer").

 

620 Memorial Drive, Suite 300, Cambridge, MA 02139.

 

 

ARCH Venture Fund VII, L.P. ("ARCH Venture Fund VII"); ARCH Venture Partners VII, L.P. ("AVP VII LP"); ARCH Venture Partners VII, LLC ("AVP VII LLC") (collectively, the "Reporting Entities" and individually, each a "Reporting Entity"); and Keith Crandell ("Crandell"), Robert Nelsen ("Nelsen") and Clinton Bybee ("Bybee") (collectively, the "Managing Directors" and individually, each a "Managing Director").  The Reporting Entities and the Managing Directors collectively are referred to as the "Reporting Persons".

8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631

 

ARCH Venture Fund VII and AVP VII LP are limited partnerships organized under the laws of the State of Delaware. AVP VII LLC is a limited liability company organized under the laws of the State of Delaware.  Each Managing Director is a US citizen.

 

 

87184Q107

 

Not Applicable.

 

(a)

Amount beneficially owned:

 

(b)

Percent of class:

 

See line 11 of the cover sheets.  The percentages set forth on the cover sheet for each Reporting Person (other than Nelsen) is based upon 26,296,436 shares of common stock outstanding as of October 31, 2017 as reported on the Issuer's Form 10-Q as filed with the Securities and Exchange Commission on November 8, 2017.  For Nelsen, the Vested Option Shares were included in the number of shares of common stock outstanding.

 

 

CUSIP No.   87184Q107

13G

Page 9 of 12 Pages

 

 

 

(c)

Number of shares as to which such person has:

 

(i)    Sole power to vote or to direct the vote:

 

(ii)   Shared power to vote or to direct the vote:

 

(iii)  Sole power to dispose or to direct the disposition:

 

(iv)  Shared power to dispose or to direct the disposition:

 

Each Reporting Person disclaims beneficial ownership of such shares of Common Stock except for the shares, if any, such Reporting Person holds of record.

Not Applicable.

 

Not Applicable.

 

Item 10.

Certification

 

 

 

 

	ARCH VENTURE PARTNERS VII, L.P.
	By:   ARCH Venture Partners VII, LLC
	its General Partner

 

	*
	Keith Crandell

 

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark McDonnell his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 7^th day of May, 2013.

 

 

 

	ARCH VENTURE PARTNERS VII, L.P.
	By:   ARCH Venture Partners VII, LLC
	its General Partner

 

	/s/ Keith Crandell
	Keith Crandell